Sisomicin is a new antibiotic produced by Micromonospora inyoensis. The in vitro activities of sisomicin, gentamicin, and tobramycin, three similar aminoglycosides, were determined against 228 clinical isolates representing 10 genera of common pathogens. No difference was noted in the activities of these antimicrobial agents when assayed by a standard broth dilution technique against Klebsiella, Enterobacter, Escherichia, Salmonella, Citrobacter, enterococci, or Staphylococcus aureus. Sisomicin was significantly more active than tobramycin against Serratia and indole-positive Proteus strains. Sisomicin was significantly more active than gentamicin against indole-negative Proteus strains and slightly more active against indole-positive Proteus strains. Tobramycin was more active than sisomicin or gentamicin against Pseudomonas and indole-negative Proteus strains. Gram-negative bacilli resistant to one of the three antimicrobial agents were not necessarily resistant to either of the other two. Activity of sisomicin was independent of the susceptibility or resistance of these isolates to nine other antimicrobial agents as assayed by the Bauer-Kirby technique. The presence of 50% human serum did not antagonize the in vitro activity of sisomicin against gram-negative isolates. Because sisomicin showed certain advantages over gentamicin or tobramycin in vitro, further investigation of this new antimicrobial agent is warranted.
Sisomicin is a new aminoglycoside antibiotic produced by Micromonospora inyoensis. Preliminary studies have shown sisomicin (antibiotic 6640) to be similar to gentamicin in both chemical structure and antibacterial spectrum. Its activity in vitro is relatively unaffected by the presence of horse serum (11, 12) . This study was designed (i) to determine the in vitro activity of sisomicin against a large number of recent clinical isolates, (ii) to compare this activity with that of gentamicin and tobramycin, two very similar antimicrobial agents, (iii) to determine the extent of cross-resistance among these three antimicrobial agents, and (iv) to determine the effect of human serum on the in vitro activity of sisomicin.
MATERIALS AND METHODS Bacterial strains. All bacterial strains were recent clinical isolates obtained from the Clinical Microbiology Laboratories of the Shands Teaching Hospital and the Veterans Administration Hospital, Gainesville, Fla. 24 Speciation of indole-positive Proteus. Indolepositive Proteus strains were speciated on the basis of H,S production and of maltose and inositol fermentation (1) .
Susceptibility testing methods. Minimal inhibitory concentrations (MIC) were determined by a serial twofold dilution technique in brain heart infusion broth (Difco). Approximately 2 x 104 to 4 x 104 colony-forming units (CFU)/ml were incubated, and tubes were examined for turbidity after incubation for 18 hr at 37 C in air. (8) (9) (10) .
Disc susceptibility tests were performed by the method of Bauer et al. (2) .
To determine the effect of serum on the in vitro activity of sisomicin, the MIC was determined as described above in 50% (by volume) heat-inactivated pooled human serum in brain heart infusion broth. This serum contained 8 (Fig.  3) .
Sisomicin was somewhat more active than gentamicin or tobramycin against 50 indolepositive Proteus strains (Fig. 4) . However, at 6.25 ,ug/ml, none of these three antimicrobial agents inhibited more than 82% of the strains tested. Therefore, these indole-positive Pro 6 .25 ug/ml was 84% for sisomicin (0), 58% for gentamicin (A), and 90%o for tobramycin (0). mined, and activities of all five drugs were compared for the individual species. Although only six strains of P. vulgaris were tested, results suggested that sisomicin and gentamicin were the most active against this species. Cross-resistance to sisomicin, gentamicin, and tobramycin. Activity of sisomicin was independent of the susceptibility or resistance of all isolates to nine other antimicrobial agents as assayed by the Kirby-Bauer technique. The nine drugs tested were ampicillin, carbenicillin, cephalothin, penicillin, chloramphenicol, kanamycin, streptomycin, polymyxin B, and tetracycline.
As noted above, organisms not inhibited by 6.25 ,ug or less of sisomicin, gentamicin, or tobramycin per ml were considered resistant. Only fourfold or greater differences in the MIC of the three drugs were considered significant.
Of the 184 strains of gram-negative bacilli included in the study, two strains of Escherichia and seven indole-positive Proteus strains were resistant to all three antimicrobial agents ( Table 2 ). The following seven strains were resistant to only two of the three drugs: one indole-negative and four indole-positive Proteus strains resistant to gentamicin and tobramycin, and one Enterobacter strain and one indole-positive Proteus strain resistant to sisomicin and tobramycin (Table 3) . Resistance to only one of the three drugs was displayed by one indole-negative Proteus strain resistant to sisomicin only, by five indole-negative Proteus strains resistant to gentamicin only, and by three Serratia strains and three indolepositive Proteus strains resistant to tobramycin only (Table 4) . These results showed that cross-resistance was not complete, at least among 19 clinical isolates representing three genera of gram-negative bacilli.
Effect of human serum on activity of sisomicin. It has been shown that calcium and of the five Pseudomonas strains tested was a significant increase (fourfold) in MIC noted in the presence of human serum; with the other four Pseudomonas strains, no significant change in MIC was observed. Of six other gram-negative bacilli tested, no effect was seen with one strain, a fourfold decrease in the MIC was noted with three, and an eightfold decrease in the MIC was noted with the remaining two strains (Table 5) . These results indicated that human serum in general did not antagonize the activity of sisomicin against Pseudomonas and increased its activity against other gram-negative bacilli.
IN VITRO EVALUATION OF SISOMICIN 27 DISCUSSION The in vitro activity of sisomicin was found to be similar to that of both gentamicin and tobramycin. However, several differences were noted. Sisomicin was significantly more active than tobramycin against Serratia and indolepositive Proteus strains, and significantly more active than gentamicin against indole-negative Proteus strains. Both sisomicin and gentamicin were less active than tobramycin against indole-negative Proteus strains and Pseudomonas strains. The results indicated that the spectrum and degree of activity of sisomicin is more similar to that of gentamicin than that of tobramycin.
The in vitro activity of five antimicrobial agents was determined against 50 indolepositive Proteus strains. When considered as Waitz et al. (11) observed only a minor effect of 50% horse serum on the in vitro activity of gentamicin. Davis and lannetta, on the other hand, observed a marked antagonistic effect of serum and calcium on the in vitro activity of gentamicin (6) and tobramycin (7) against Pseudomonas. It should be pointed out that lower concentrations of serum and calcium were used in these latter studies. Therefore, a comparison of the effect of serum on sisomicin, gentamicin, and tobramycin cannot be made.
Results of the study indicated: (i) that against certain bacterial species sisomicin has greater activity in vitro than gentamicin or tobramycin, (ii) that gram-negative bacilli resistant to either gentamicin or tobramycin or to both are not necessarily resistant to sisomicin, and (iii) that human serum does not have an antagonistic effect on the in vitro activity of sisomicin. In view of these potential advantages, further investigation of this new antimicrobial agent is warranted.
